Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00462735
Status:
COMPLETED
Last Update Posted:
2018-03-13
First Post:
2007-04-18
Brief Title:
Fluorouracil Hydroxyurea Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Sponsor:
Johnny Kao
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
Phase II Study of Concomitant Fluorouracil Hydroxyurea Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
For advanced head and neck cancer combined radiation and chemotherapy prevents recurrences and for many patients improves survival While combined cisplatin and radiation or cetuximab and radiation is more effective than radiation alone approximately 50 of these patients will still recur A more aggressive approach may be needed for these patients to prevent recurrence and death The strategy of using multiple chemotherapy drugs with radiation given twice a day has been tested at Mount Sinai and University of Chicago Approximately 80 of patients are cured with this strategy While cure rates are higher than standard chemotherapy and radiation and the treatment is tolerable side effects during treatment are common We propose replacing a chemotherapy drug with a less toxic targeted therapy called cetuximab Our goal is to reduce toxicity while maintaining or improving cure rates for these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None